Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Pazopanib in Metastatic Soft Tissue Sarcoma
NCT05679921Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in soft tissue sarcoma (STS) (2 arms), sponsored by Yonsei University. Primary endpoint: Progression Free Rate at 12 weeks. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05679921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679921.